Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of the Netherlands

Objectives: Policy makers increasingly seek to complement data from clinical trials with information from routine care. study aims to provide a detailed account of the hospital resource use and associated costs of patients with advanced breast cancer in The Netherlands. Methods: Data from 597 patients with advanced breast cancer, diagnosed between 2010 and 2014, were retrieved from Southeast Netherlands Advanced Breast Cancer Registry. Database lock for this study was in October 2017. We report observed hospital costs for different resource categories and the lifetime costs per patient, adjusted for censoring using method. The relationship between patients' characteristics and costs was studied using multivariable regression. Results: The average (SE) lifetime hospital costs of patients with advanced breast cancer were (sic)52 709 (405). Costs differed considerably between patient subgroups, ranging from (sic)29 803 for patients with a triple-negative subtype to (sic)92 272 patients with hormone receptor positive and human epidermal growth factor receptor 2 positive cancer. Apart from cancer subtype, several other factors, including age and survival time, were independently associated with patient lifetime costs. Overall, a large share of costs was attributed to systemic therapies (56%), predominantly to a few expensive agents, such as trastuzumab (15%), everolimus (10%), and bevacizumab (9%), as well as to inpatient hospital days (20%). Conclusions: This real-world study shows the high degree of variability in hospital resource use and associated costs advanced breast cancer care. The presented resource use and costs data provide researchers and policy makers with figures for economic evaluations and budget impact analyses.